1-4 of 4
Li Yan
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract PR06: Phase 1b dose-escalation study of trametinib (MEKi) plus palbociclib (CDK4/6i) in patients with advanced solid tumors

Ryan J. Sullivan, Rodabe N. Amaria, Donald P. Lawrence, John Brennan, Cathie Leister, Rajendra Singh, Jeff Legos, Holger Thurm, Li Yan, Keith T. Flaherty, Michael A. Davies, Jeffrey Sosman
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): PR06.
https://doi.org/10.1158/1535-7163.TARG-15-PR06
Published: 01 December 2015
View article titled, Abstract PR06: Phase 1b dose-escalation study of trametinib (MEKi) plus palbociclib (CDK4/6i) in patients with advanced solid tumors
Journal Articles

MK-2206, a Novel Allosteric Inhibitor of Akt, Synergizes with Gefitinib against Malignant Glioma via Modulating Both Autophagy and Apoptosis

Yan Cheng, Yi Zhang, Li Zhang, Xingcong Ren, Kathryn J. Huber-Keener, Xiaoyuan Liu, Lei Zhou, Jason Liao, Heike Keihack, Li Yan, Eric Rubin, Jin-Ming Yang
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (1): 154–164.
https://doi.org/10.1158/1535-7163.MCT-11-0606
Published: 09 January 2012
View article titled, MK-2206, a Novel Allosteric Inhibitor of Akt, Synergizes with Gefitinib against Malignant Glioma via Modulating Both Autophagy and Apoptosis
Open the PDF for MK-2206, a Novel Allosteric Inhibitor of Akt, Synergizes with Gefitinib against Malignant Glioma via Modulating Both Autophagy and Apoptosis in another window
Includes: Supplementary data
Journal Articles

Abstract B135: First‐in‐man, first‐in‐class phase I study of two schedules of MK‐2206, a novel oral Akt inhibitor, in patients (pts) with advanced solid tumors, including ovarian and castration resistant prostate cancer (CRPC)

Timothy A. Yap, Kyriakos Papadopoulos, Ivy Fearen, Christopher Carpenter, Liliana Delgado, Adekemi Taylor, Julia Domsch, David Olmos, Andre T. Brunetto, Daniel S. Tan, Shaun Decordova, Simon P. Heaton, Michelle D. Garrett, Amita Patnaik, Daniel Sullivan, Li Yan, Johann S. de Bono, Anthony W. Tolcher
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): B135.
https://doi.org/10.1158/1535-7163.TARG-09-B135
Published: 10 December 2009
View article titled, Abstract B135: First‐in‐man, first‐in‐class phase I study of two schedules of MK‐2206, a novel oral Akt inhibitor, in patients (pts) with advanced solid tumors, including ovarian and castration resistant prostate cancer (CRPC)
Journal Articles

Neutralization of CCL2 inhibits tumor angiogenesis and pancreatic tumor growth

Linda Snyder, Prabakaran Kesavan, Elizabeth Kaiser, Kelly Rudnick, Frank McCabe, Hillary Millar, Marian Nakada, Li Yan
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): A69.
Published: 01 November 2007
View article titled, Neutralization of CCL2 inhibits tumor angiogenesis and pancreatic tumor growth